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KESAN IMMUNOREGULATORI KLON BCG REKOMBINAN (rBCG) 
YANG MENGEKSPRESKAN TERMINUS C PROTEIN PERMUKAAN 
MEROZOITE-1 (MSP-1C) DARIPADA Plasmodium falciparum 
KE ATAS SEL MAKROFAJ MENCIT 
 
ABSTRAK 
 
Fagositosis oleh makrofaj adalah mekanisme pertahanan pertama terhadap jangkitan 
parasit malaria dalam sistem imun semula jadi. Setelah diaktifkan, makrofaj akan 
bertindak sebagai sel radang dan sel anti-mikrob melalui rembesan sitokin pro-
inflamatori dan nitrik oksida (NO). Dalam kajian ini, kesan immunoregulatori klon 
BCG rekombinan (rBCG) yang mengekspreskan terminus C protein permukaan 
merozoite-1 19-kDa (MSP-1C) daripada Plasmodium falciparum ke atas sel 
makrofaj mencit, J774A.1 telah dikaji. Keupayaan klon rBCG merangsang 
fagositosis, pertumbuhan makrofaj, pengekspresan reseptor toll-like (TLR), 
pengeluaran sitokin pro-inflamatori, NO dan sintase nitrik oksida indusibel (iNOS) 
oleh makrofaj dalam kehadiran atau ketiadaan lipopolisakarida (LPS) atau LPS + 
interferon (IFN)-γ telah ditentukan. Keputusan menunjukkan bahawa klon rBCG 
mampu meningkatkan aktiviti fagositik, pengekspresan TLR dan pengeluaran sitokin 
pro-inflamatori seperti tumor nekrosis factor (TNF)-α dan interleukin (IL)-1β serta 
NO dan iNOS oleh makrofaj yang telah dijangkiti apabila dibandingkan dengan 
BCG. Keputusan juga menunjukkan bahawa klon rBCG mengurangkan pengeluaran 
IL-12 p40 dan pertumbuhan makrofaj yang telah dijangkiti serta pertumbuhan klon 
rBCG itu sendiri apabila dibandingkan dengan BCG. Kesan immunoregulatori ini 
adalah penting dalam tindak balas imun semula jadi terhadap parasit malaria. Oleh 
itu, klon rBCG ini mungkin berpotensi digunakan untuk mengawal jangkitan 
malaria. 
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IMMUNOREGULATORY EFFECTS OF RECOMBINANT BCG (rBCG) 
EXPRESSING C-TERMINUS OF MEROZOITE SURFACE PROTEIN-1  
(MSP-1C) OF Plasmodium falciparum ON MOUSE MACROPHAGE 
 
ABSTRACT 
 
Macrophage phagocytosis acts as the first line of defence against malaria parasites 
infection in the innate immune system. Once activated, macrophages act as 
inflammatory and microbicidal cells through the production of pro-inflammatory 
cytokines and nitric oxide (NO). In this study, the immunoregulatory effects of a 
recombinant BCG (rBCG) clone expressing the 19-kDa C-terminus of the merozoite 
surface protein-1 (MSP-1C) of Plasmodium falciparum was examined on the mouse 
macrophage cell line J774A.1. The ability of the rBCG clone to stimulate 
phagocytosis, macrophage viability, expression of toll-like receptors (TLRs) and 
production of pro-inflammatory cytokines, NO and inducible nitric oxide synthase 
(iNOS) by the macrophages in the presence or absence of lipopolysaccharide (LPS) 
or LPS + interferon (IFN)-γ was determined. The results demonstrated that the rBCG 
clone was able to enhance the phagocytic activity, TLRs expression and production 
of pro-inflammatory cytokines such as tumor necrosis factor (TNF)- and interleukin 
(IL)-1 as well as NO and iNOS of the infected macrophages when compared to 
parent BCG. The results also demonstrated that the rBCG clone reduced the IL-12 
p40 production and the viability of the infected macrophages as well as the growth of 
the rBCG clones when compared to BCG. These immunoregulatory effects are 
important in innate immune response against malaria parasite. Thus, this rBCG clone 
may potentially be used to control malaria infection. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 History of Malaria 
Many ancient histories already described the symptoms of malaria. The word malaria 
came from an Italian word, “mal’aria” which means “bad or evil air”. In ancient 
Chinese, before 4700 years ago, it had been described in the Nei Ching (the Canon of 
Medicine by Emperor Huang Ti), where the symptom apparently refers to repeated 
fever associated with enlarged spleens and a tendency to epidemic occurrence. 
Sumerian and Egyptian texts, 3500 to 4000 years ago, also described the fever and 
spleens enlargement that suggested to malaria symptoms. A Greek physician, 
Hippocrates who lived in the fifth century B.C., was the first to describe the clinical 
picture of malaria. While in 25
th
 B.C., Celsus recorded the various types of malaria in 
the literature and depopulation of rural area. In Sanskrit medical texts, the symptoms 
of malaria were described and attributed to the bites of certain insects (Gilles, 2002). 
 
A Qinghao plant known as sweet wormwood was first described for its antifever 
properties during the second century B.C. in ancient Chinese. In 1971, a Chinese 
scientist had found an active ingredient from the Qinghao known as artimisinin. In 
the seventeenth century, Indian tribes used the Peruvian bark as the treatment for 
fevers. It is only in 1820 that Pelletier and Caventou in France had successfully 
isolated an active compound named quinine from the Peruvian bark. Both artimisinin 
and quinine are now known as very effective antimalarial drugs (Gilles, 2002).  
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In 1880 Charles Leveron, a French army surgeon who worked in Algeria, first saw 
and described malaria parasites in the red blood cells of a patient. However, how this 
disease was transmitted from a person to a person remains unknown until late 1987. 
It was Ronald Ross, a British officer in the Indian Medical Service, who first 
discovered that malaria parasites could be transmitted from an infected patient to 
mosquitoes. The whole picture of this malaria parasites complex life cycle was then 
became clear as a result from studies by a group of Italian researchers led by Grassi 
from 1898 to 1899 (Gilles, 2002). 
 
1.2 Malarial burden 
1.2.1 Worldwide 
World Health Organization (WHO) estimated that 2.8 billion people (half of the 
world’s population) are living in malaria transmission risk areas, where 1.1 billion 
people (one fifth of this population) live in areas with a high risk of malaria 
transmission (WHO, 2012a). It is found that African region has the largest number of 
people living in areas with high risk of malaria transmission followed by South-East 
Asia region. However, the largest populations at some risk of malaria transmission 
are found in South-East Asia and Western Pacific regions. Figure 1.1 shows areas 
where malaria transmission occurs.  
 
In 2011, it is estimated that there are 219 million cases of malaria worldwide, where 
79 % cases were in African region, 15 % cases were in South-East Asia and 5% in 
Eastern Mediterranean region. Among the malaria cases, 91 % were due to 
Plasmodium falciparum infection. It is estimated that approximately 660 000 malaria 
deaths occurred worldwide in 2011, of which 90 % deaths were in African region,     
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6 % deaths in the South-East Asia and 2 % deaths in Eastern Mediterranean region. 
From this total malaria death globally, 86 % deaths were children under five years 
old (WHO, 2012a). 
 
1.2.2 Malaysia 
Most malaria transmission areas in Malaysia are in Sabah, Sarawak and in the 
interior central region of Peninsular Malaysia where Perak, Pahang and Kelantan 
share their borders. In 2011, it is estimated that more than 1 million people live in 
active malaria transmission areas. Figure 1.2 shows the distribution of confirmed 
malaria cases in Malaysia. It is estimated that 1.6 million people are suspected with 
malaria in Malaysia, where P. vivax infection was the main cause of the malarial 
infection followed by P. falciparum infection or mixed infections (WHO, 2012a).  
 
Sabah and Sarawak are the major contributors for malaria cases in Malaysia where 
the highest cases were in Sabah with 12.19 per 10 000 populations followed by 
Sarawak with 7.28, Kelantan with 1.68 and Pahang with 1.14 (MOH, 2009). In 2009, 
the Ministry of Health Malaysia (MOH) reported that the number of malaria deaths 
was the highest in Sabah where 13 people died followed by Sarawak with eight, 
Selangor with two and one each for Perak, Pahang and Terengganu (MOH, 2009). 
However, the mortality rate caused by malaria was 0.06 per 100 000 populations in 
2011 in Malaysia (MOH, 2012). 
 5 
 
  
    
 6 
 
1.3 Malaria parasite 
1.3.1 Characterization   
Malaria is caused by protozoan parasites of the genus Plasmodium, family 
Plasmodiidae, suborder Heamosporidiidae, order Coccidia, which can be found in 
the blood of mammals, reptiles and birds. They are recognized taxonomically by two 
types of asexual division which are schizogony, in the vertebrate host and sporogony, 
in the insect vector (Sinden & Gilles, 2002). Five malaria parasites are found in 
humans. They are P. falciparum (Snow et al., 2005), P. vivax (Mendis et al., 2001), 
P. ovale (Collins & Jeffery, 2005), P. malariae (Collins & Jeffery, 2007), and P. 
knowlesi (Singh et al., 2004). Each of them differs in the severity of the disease 
(Wipasa et al., 2002) and their microscopic appearance in blood stage (Figure 1.3). 
Specific name is used to describe the disease such as falciparum malaria, for P. 
falciparum infection and vivax malaria, for P. vivax infection. However, malaria 
cause by P. malariae infection is known as quartan malaria (Sinden & Gilles, 2002).  
 
Althougth P. falciparum and P. vivax are the major causes in malaria infection, it is      
P. falciparum that causes the most severe form of malaria resulting in major 
morbidity and mortality (Snow et al., 2005; WHO, 2012). This is because                
P. falciparum multiples rapidly in the blood, thus causing anemia in the subject. A 
non-immune subject not treated with specific drugs can end in acute malaria and be 
fatal (Sinden & Gilles, 2002). Thus, over the past years, many studies have been 
done on this P. falciparum species.  
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Malaria caused by the other four human malaria parasites is rarely fatal. P. vivax and 
P. ovale can relapse, activate and invade the blood for several months or years after 
infection because of their unique life cycle which they have dormant liver stages 
called hypnozoites (Cogswell, 1992). However, P. ovale differs from P. vivax 
because it can infect individuals who are negative for the Duffy blood group 
(Mercereau-Puijalon & Menard, 2010). P. malariae can remain in blood after 
infection for a life time without any symptoms and as for P. knowlesi, it causes 
various clinical symptoms and can rapidly progress from uncomplicated to severe 
malaria because of its 24 hours replication cycle (Greenwood et al., 2008). 
 
1.3.2 Life cycle 
All malaria parasites have a complex life cycle involving two types of host as 
illustrated in figure 1.4. The female Anopheles mosquito is the main host in which 
sexual stage of parasite life cycle occurs and human is the intermediate host in which 
asexual development occurs. During a blood meal, an infected female Anopheles 
mosquito transmits the Plasmodium parasite into the human bloodstream by injecting 
the sporozoites in their salivary glands (Eyles et al., 1960; Paul et al., 2004). The 
sporozoites rapidly enter the hepatocytes and replicate into pre-erythrocytic schizont 
containing 10,000 to 30,000 merozoites or more in the case of P. falciparum (Amino 
et al., 2006). This pre-erythrocytic phase last from 5 to 15 days depending on the 
Plasmodium species, where 5 to 6 days for P. falciparum, 8 days for P. vivax, 9 days 
for P. ovale, 13 days for P. malariae and 8 to 9 days for P. knowlesi (Singh et al., 
2004). In P. vivax and P. ovale, hypnozoite may occur when the sporozoite remain 
dormant for weeks to months in the liver before developing into pre-erythrocytic 
schizonts. This is due to the genotypically different form of the hypnozoites from the 
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sporozoites that cause acute infection soon after injection of Plasmodium (Cogswell, 
1992; Collins, 2007).  
 
The merozoites that develop in the hepatocyte are transferred from the liver to the 
bloodstream by merosome, a host cell-derived vesicle, which protects the merozoites 
from phagocytosis by Kupffer cells (Silvie et al., 2008). Merozoites invade the 
erythrocytes (red blood cells) and undergo erythrocytic phase, in which each 
merozoite develops through the stages of ring, trophozoite, and schizont. At the end 
of erythrocytic phase, the infected erythrocytes rupture to release the merozoites. 
These then invade new erythrocytes to repeat the erythrocytic cycle which occur 
every 48 hours for P. falciparum, P. vivax, and P. ovale, 72 hours for P. malariae, 
and 24 hours for P. knowlesi (Greenwood et al., 2008). The rupture of erythrocytes 
releases toxins that activate macrophages to produce cytokines, resulting in the 
symptoms of malaria.  
 
Some merozoites can differentiate into the sexual stages gametocytes. The male and 
female gametocytes in human host are then transmitted to mosquito host via its bites. 
The sexual phase of malaria parasite’s life cycle is continuing in this vector. The 
male and female gametes fertilize to form zygotes, which later develop into 
ookinetes. The ookinetes enter the midgut wall of the mosquito to develop into 
oocysts, which later produce thousands of active sporozoites. The sporozoites are 
released and travelled to the mosquito salivary gland and transmitted to new human 
host by another mosquito bite, where the parasite’s life cycle starts over again 
(Matuschewski, 2006). 
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Figure 1.4: The life cycle of malaria parasite. Figure is adapted from Johns 
Hopkins Bloomberg School of Public Health (2006). 
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1.4 Pathophysiology of malaria parasites 
1.4.1 Pathogenesis of malaria 
The infections of the erythrocytes by malaria parasite that undergoes asexual blood 
cycle are the cause of malarial illness (Tilley et al., 2011). All types of malaria have 
common symptoms such as fever which are normally accompanied by nausea, 
aching joints and muscles, headache and chills which is due to the release of parasite 
products from rupture host cells activating inflammatory cells such as macrophages 
(Metzger et al., 1995). However, most cases with P. falciparum may progress into 
severe malaria.  
 
Severe malaria occurs when the erythrocytes that are infected with malaria parasite 
lead to progressive and dramatic structural and biochemical changes which can be 
worsen into life-threatening complications. The majority of severe malaria is caused 
by P. falciparum infection. However, there are also reports on death by P. vivax and 
P. knowlesi infections (Anstey et al., 2009; Cox-Singh et al., 2010). Parasite 
biomass, malaria toxins and inflammatory response, cytoadherence, rosetting and 
sequestration, deformability and rigidity of erythrocytes, endothelial activation, 
dysfunction and injury, and altered trombostasis are the pathophysiological factors of 
malaria. These pathophysiological factors may result in complications of severe 
malaria including cerebral malaria, hypoglycemia, metabolic acidosis, renal failure, 
and respiratory distress (Anstey et al., 2009).  
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A structural change in the infected erythrocytes leads to adhesiveness of the 
erythrocytes, where the infected erythrocytes adhere to the capillary and endothelium 
and also adhere to uninfected erythrocytes resulting in red cell rosettes. This 
cytoadherence promotes sequestration of the parasites in the heart, lung, brain, liver, 
kidney, and placenta. Sequestration increases the adhesion of the infected 
erythrocytes to endothelium which allows them to avoid from clearance by the 
spleen, thus blocking blood flow and limits the local oxygen supply. These 
encourage the development of severe malaria disease (Ho & White, 1999; van der 
Heyde et al., 2006; Horata et al., 2009). Figure 1.5 shows the cytoadherence and 
rosetting in postcapillary vasculature. 
 
1.4.2 Immunity against malaria 
Normally, malaria infection leads to only a partial or short lived immunity that is 
unable to protect the individual against a new infection. Immunity to malaria is a 
multi-factorial process that involves both innate and adaptive immune system 
(Doolan et al., 2009; Vasan & Tsuji, 2010). Most of these studies have been 
concentrated at pre-erythrocytic (sprorozoites) and asexual erythrocytic (merozoites) 
stages. However, in this study the focus is on inflammatory mediator in antiparasitic 
immune responses caused by the parasite in asexual erythrocytic stage. Figure 1.6 
shows the mechanisms of immunity to asexual erythrocytic stage of malaria. 
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Figure 1.5: The cytoadherence and rosetting in postcapillary vasculature. Figure 
is adapted from Chen et al. (2000). 
 
 14 
 
  
 15 
 
1.4.2.1 Innate immunity 
Innate immunity has a crucial role in eliminating malaria parasites from the infected 
host. Several studies have found that monocytes, macrophages, NK cells and 
neutrophils appear to be involved in clearing malaria parasites in innate immunity. 
Moreover, most studies have considered the effectiveness of monocyte-macrophage 
at phagocytosing infected erythrocytes compared to neutrophils (Taverne et al., 
1982).  
  
At asexual erythrocytic stage, the newly formed merozoite and waste such as red cell 
membrane and parasite products, including glycosyl phosphatidyl inositol (GPI) 
(Schofield & Hackett, 1993) and malaria pigment (hemazoin) (Pichyangkul et al., 
1994), are released into the blood by the rupture of infected erythrocytes. It is found 
that GPI activates monocytes, neutrophils and macrophages through the toll-like 
receptor (TLR) 2 and to a lesser extent TLR4 (Krishnegowda et al., 2005), whereas 
hemazoin recognition by TLR9 is still controversial (Shio et al., 2010).  Activated 
macrophages lead to secretion of pro-inflammatory cytokines such as tumor necrosis 
factor-α (TNF-α), interleukin-1 (IL-1), IL-12, IL-6, and macrophage colony–
stimulating factor, as well as superoxide and nitric oxide (NO), where they are 
largely attributed to the manifestation of malaria symptoms (Hunt & Grau, 2003; 
Dhangadamajhi et al., 2009) as well as to control parasite growth (Stevenson & 
Riley, 2004). 
 
TNF-α is typically involved in pathology and immunity to malaria infection. 
Although, morbidity and mortality in individuals with malaria are associated with the 
high level of TNF-α, the cytokine also plays an important role in killing parasite and 
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inhibiting parasite replication (Grau et al., 1989; Kern et al., 1989; Kwiatkowski et 
al., 1989; Clark et al., 1990; Kwiatkowski et al., 1990). Moreover, TNF-α also 
stimulates macrophages to produce inducible nitric oxide synthase (iNOS), through 
generation of NO, which is able to kill the parasites directly (Rockett et al., 1991; 
Rockett et al., 1992). Most of the malaria symptoms such as fever, headache, nausea, 
diarrhea and thrombocytopenia are associated with the production of TNF-α 
(Schwartz et al., 1989). Furthermore, along with interferon (IFN)-γ, which is mainly 
produced by NK cells and Th1 cells, TNF-α appears vital in controlling parasitemia 
(Kremsner et al., 1995) and stimulating macrophage phagocytic activity, which 
enhances parasite clearance (Newsome, 1984). However, over production of these 
inflammatory mediators together with NO will lead to malarial anemia (Clark & 
Cowden, 2003; Lyke et al., 2004). 
 
Another endogenous pyrogen that promotes an acute inflammatory response is IL-1β, 
which contributes as the first line defence against infected erythrocytes (Dinarello, 
2004). Together with TNF-α, IL-1β enhances the production of NO and IFN-γ in in 
vivo study (Rockett et al., 1994). A previous study showed that IL-1β protects against 
the development of cerebral malaria as well as controlling parasitemia (Curfs et al., 
1990). However, excess production of IL-1β is likely to be involved in inflammatory 
disease, and aids in anemia (Dinarello, 2005; Pascual et al., 2005). Interestingly, it is 
reported that haplotypes of IL-1β promoter polymorphisms promote the development 
of severe malaria anemia and are correlated with the reduction of IL-1β production, 
whereas haplotypes that promote protection against severe malaria anemia produce 
elevated IL-1β (Ouma, 2008). 
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IL-12, a heterodimeric protein composed of the 35 and 40 kDa subunits, is secreted 
from dendritic cells, monocytes, macrophages and B-cells in response to bacterial 
cell wall components (Gately et al., 1998; Trinchieri & Frank, 1998; Mosser & arpt, 
1999). IL-12 promotes production of IFN-γ from NK cells and Th1 cells (Gately et 
al., 1998; Trinchieri & Frank, 1998), which then induce macrophage microbicidal 
functions including elevation of IL-12 production. It has been demonstrated that high 
level of IL-12 is effective in inducing protective immunity against blood-stage 
infection in the murine model (Crutcher et al., 1995; Mohan et al., 1997; Sam & 
Stevenson, 1999). However, it is shown that low level of IL-12 may aid in anemia 
and dyserythropoiesis (Mohan & Stevenson, 1998). Other studies show that 
suppression of IL-12 in children with severe malaria anemia was associated with 
high hemazoin concentration, where phagocytosis of hemazoin induces up-regulation 
of IL-10. This anti-inflammatory cytokine in turn suppresses IL-12 production (Luty 
et al., 2000; Keller et al., 2006). 
 
NO is both protective and pathogenic in malaria. Generation of NO from iNOS 
occurs in monocytes, macrophages and neutrophils (Perkins et al., 1999). Basically, 
pro-inflammatory cytokines such as IL-12, IFN-γ and TNF-α increase iNOS-
generated NO production, whereas anti-inflammatory cytokines include IL-10 and 
TGF-β down-regulate iNOS expression (Geller & Billiar, 1998). NO has potent 
parasiticidal properties against P. falciparum (Rockett et al., 1991) and serves as an 
important effector in limiting parasitemia (Kremsner et al., 1996). However, excess 
NO production promotes anemia (Keller et al., 2004). As with NO, the reactive 
oxygen species (ROS) is also both protective and pathogenic in malaria. ROS seems 
to control parasitemia (Postma et al., 1996; Greve et al., 1999) but at the same time 
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may cause damage to the erythrocytic membrane, which then lead to severe malaria 
anemia (Griffiths et al., 2001; Narsaria et al., 2012). 
 
1.4.2.2 Adaptive immunity 
The CD4
+
 T and CD8
+
 T cells as well as B cells, which are involved in adaptive 
immunity, are rapidly activated during erythrocytes infection by merozoites. 
However, CD4
+ 
T cells play more roles in protective immunity against asexual 
erythrocytic stage (Li et al., 2001). CD4
+
 T cells can be separated into two functional 
subsets, T helper (Th) 1 and Th2. The Th1 cells mediate cellular or innate immune 
response, while the Th2 cells mediate humoral immune response. It seems that 
production of cytokine such as IL-2, IFN-γ, and TNF-α by Th1 cells can activates 
macrophages, while Th2 produces anti-inflamatory cytokines such as IL-4, IL-5, IL-
6, IL-10, and IL-13 which involved in maturation of B cells to plasma cells 
(Mosmann & Sad, 1996). Thus, both the cellular and humoral immune responses are 
required to control the parasites infection (Troye-Blomberg et al., 1994; Helmby et 
al., 1998; Torre et al., 2002). Previous studies revealed that Th1 cells give protection 
via NO-dependent mechanism, while Th2 cells give protection by the production of 
parasite-specific IgG1 (Taylor-Robinson et al., 1993).  
 
  
 19 
 
1.5 Malaria diagnosis 
Malaria diagnosis is usually performed by light microscopic examination of Giemsa 
stained blood slides for the detection of Plasmodium parasites and is currently 
remain as the gold standard (Makler et al., 1998; Hawkes & Kain, 2007; Tek et al., 
2010). However, this method requires special training and is not reliable when 
performed by non experts, which may result in unnecessary or inappropriate 
treatment of the patient (Coleman et al., 2002; Bates et al., 2004; Rafael et al., 2006).  
 
The presence of malaria parasites also can be detected by other malaria diagnostic 
methods, such as quantitative buffy coat (QBC) (Moody, 2002) for staining the 
malaria parasites, enzyme-linked immunosorbant assay (ELISA) (Noedl et al., 2006) 
which is based on detection of anti-malarial antibodies or  polymerase chain reaction 
(Hanscheid & Groubusch, 2002; Snounou, 2007) that detects the DNA of malaria 
parasites. However, these methods require expensive and special equipments which 
most endemic areas have limited resources (Hanscheid & Groubusch, 2002; Daar et 
al., 2007; Mens et al., 2008). 
 
These limitations have prompted the development of new simple methods to detect 
the presence of Plasmodium parasites which are known as the rapid diagnostic tests 
(RDTs). These tests do not rely on special equipment, fast, easy to perform and cost 
less whereby suitable for endemic and poor areas (Moody, 2002; Wongsrichanalai et 
al., 2007; Murray et al., 2008; Drakeley & Reyburn, 2009; Mawili-Mboumba et al., 
2010). RDTs are immunochromatographic assays and are based on the recognition of 
Plasmodium parasite antigen by monoclonal antibodies incorporated into a test strip. 
Currently, three types of antigens are used in commercialized RDTs, which are 
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parasite-specific aldolase, found in all malarial species, parasite lactate 
dehydrogenase (pLDH) and histidine-rich protein 2 (HRP-2), found in P. falciparum 
only (Cheng & Bell, 2006; Hopkins et al., 2007; Wongsrichanalai et al., 2007).  
 
1.6 Prevention of malaria 
Vector control or avoidance of mosquito bites is one of the effective ways to prevent 
malaria. As recommended by World Health Organization, insecticide treated nets 
(ITN) and indoor residual spraying (IRS) are the most potential tools to control 
malaria parasites transmission by reducing lifespan of female Anopheles mosquito 
and human contact (WHO, 2012). Each year, the use of ITN such as long lasting 
insecticidal net (LLIN) has been expended to all people in risk area for malaria. It is 
reported that LLIN is the most effective and cost-effective prevention for malaria. 
IRS is highly recommended for high risk area for malaria transmission. 
  
There are 12 insecticides for IRS which is used base on resistance, the residual 
efficacy of the insecticide, cost, safety and the type of surface to be sprayed. In areas 
where IRS is the main vector control, the used of pyrethroid for IRS is not 
recommended to be use with LLIN. This is because pyrethroid is the only class of 
insecticide that used on LLIN. The combination of IRS and ITN effectively increase 
vector control (Kleinschmidt et al., 2009). Therefore, when using the combination of 
IRS and ITN, a non-pyrethroid insecticide should be used for IRS.  
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1.7 Treatment against malaria 
A patient infected with malaria can has a complete recovery if early and proper 
treatment has been given. Antimalarial drugs may have several uses and effects, thus 
treatment for malaria depends on several factors such as the species of the malaria 
parasite, the sensitivity of the parasites to the antimalarial drugs, the severity of 
infection, the immunity status of the host, and drug cost (Warrell et al., 2002; 
Griffith et al., 2007). 
 
Uncomplicated P. falciparum malaria is symptomatic malaria without signs of 
severity. According to WHO (2010), the use of artemisinin-based combination 
therapy (ACT) is the most effective current treatment for uncomplicated malaria. 
ACT produces rapid clearance of parasitaemia and is able to reduce gametocytes 
carriage, thus reducing the transmission of malaria parasites (WHO, 2010).  
 
Severe P. falciparum malaria patient may rapidly progress to death if not treated with 
prompt and appropriate treatment (Trampuz et al., 2003). Other than symptomatic 
malaria, a patient who is suffering from severe P. falciparum malaria has one or few 
severity signs such as impaired consciousness, prostration, respiratory distress, 
hypoglycaemia and severe anaemia.  Rather than quinine, parenteral antimalarial 
treatment in full doses of artesunate (an artemisinin derivative) can reduce the risk of 
death from severe malaria in adult and children followed by effective and complete 
treatment using a full course of ACT (WHO, 2010).  
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Malaria infection with P. vivax, P. ovale, P. malariae or P. knowlesi is usually 
treated as non severe malaria. Both blood and liver stages should be given treatment 
for P. vivax and P. ovale infections. For blood stage infection, P. vivax and P. ovale 
can be treated with chloroquine or amodiaquine, mefloquine, quinine and ACT if 
they are resistant to chloroquine. While for liver stage infection, P. vivax can be 
treated with primaquine to prevent the relapse (Galappaththy et al., 2007; WHO, 
2010). For infection with P. malariae and P. knowlesi, treatment with chloroquine is 
considered to be sufficient. However, they should be treated with the standard 
regimen for chloroquine-resistant malaria to achieve radical cure (Maguire et al., 
2002; WHO, 2010).  
 
1.8 Development of malaria vaccine 
Vaccine development is essential in improving the public health and to protect 
human against malaria due to the emergence of drug-resistant parasites and 
insecticide-resistant vectors in many parts of the world (Malkin et al., 2006; Ro et 
al., 2006). In 2002, the P. falciparum genome project has completed. From here, 
researchers have identified hundreds of parasite protein that could be developed as 
malaria vaccine candidates (Tongren et al., 2004). Figure 1.7 shows several malaria 
vaccine candidates that have been evaluated in clinical trials.  
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1.8.1 Different target stages of malaria vaccine 
Because of the complexity of malaria parasite life cycle, the development of effective 
malaria vaccine should be targeted at different parasite stages which are pre-
erythrocytic stage (sporozoites and hepatic stages), asexual erythrocytic stage 
(merozoites stage) and sexual stage (Girard et al., 2007; Thera et al., 2012). Of those 
target stages, the asexual erythrocytic stage based vaccines are the most critical 
(Figure 1.8), since at this stage the infected patient will develop severe malaria and 
clinical malaria illness (Doolan et al., 2009). 
 
 
Figure 1.8: Different target stages of malaria vaccine development. The 
pathological asexual stages are highlighted as a critical target for vaccine 
development. Figure is adapted from Taylor-Robinson (2010). 
 
 
